Intended for healthcare professionals

CCBYNC Open access
Research

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j510 (Published 10 February 2017) Cite this as: BMJ 2017;356:j510

Re: Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

I did not see it mentioned, but I presume that the reduced dabigatran and apixiban were given Twice daily and the rivaroxiban and warfarin Once daily, Is this correct? Any information on compliance and, if so, how the data were affected?

DR

Competing interests: No competing interests

19 February 2017
Donald M Rocklin
Cardiologist
Yale
New Haven